{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T02:49:17Z","timestamp":1775616557690,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.exer.2018.05.027","type":"journal-article","created":{"date-parts":[[2018,5,28]],"date-time":"2018-05-28T16:34:29Z","timestamp":1527525269000},"page":"98-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies"],"prefix":"10.1016","volume":"174","author":[{"given":"Yong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna Marie","family":"Busoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben Alfyan Achirn","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Queenie Shu Woon","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin Siew Wei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veluchamy Amutha","family":"Barathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay Ji-Ye","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5265-4933","authenticated-orcid":false,"given":"Walter","family":"Hunziker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanjin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tien Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2018.05.027_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1586\/eop.13.17","article-title":"Targeting neovascularization in ischemic retinopathy: recent advances","volume":"8","author":"Al-Shabrawey","year":"2013","journal-title":"Expet Rev. Ophthalmol."},{"key":"10.1016\/j.exer.2018.05.027_bib2","series-title":"Australian Public Assessment Report for Ranibizumab Properietary Product Name : Lucentis Sponsor","author":"AusPAR","year":"2011"},{"key":"10.1016\/j.exer.2018.05.027_bib3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/path.2611","article-title":"Muller cell-derived VEGF is a significant contributor to retinal neovascularization","volume":"219","author":"Bai","year":"2009","journal-title":"J. Pathol."},{"key":"10.1016\/j.exer.2018.05.027_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.preteyeres.2006.05.003","article-title":"Muller cells in the healthy and diseased retina","volume":"25","author":"Bringmann","year":"2006","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.exer.2018.05.027_bib5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.exer.2018.05.027_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0034-5288(18)31228-1","article-title":"Retinal vascular patterns in domestic animals","volume":"47","author":"De Schaepdrijver","year":"1989","journal-title":"Res. Vet. Sci."},{"key":"10.1016\/j.exer.2018.05.027_bib7","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1006\/exer.1996.0163","article-title":"Study of choroidal blood flow by comparison of SLO fluorescein angiography and microspheres","volume":"63","author":"Duijm","year":"1996","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2018.05.027_bib8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.exer.2004.09.013","article-title":"Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown","volume":"80","author":"Edelman","year":"2005","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2018.05.027_bib9","series-title":"European Medicines Agency Assessment Report Committee for Medicinal Products for Human Use (CHMP) Eylea Aflibercept","author":"EMA","year":"2012"},{"key":"10.1016\/j.exer.2018.05.027_bib10","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1017\/S0952523800006799","article-title":"Regional topography of rod and immunocytochemically characterized \"blue\" and \"green\" cone photoreceptors in rabbit retina","volume":"12","author":"Famiglietti","year":"1995","journal-title":"Vis. Neurosci."},{"key":"10.1016\/j.exer.2018.05.027_bib11","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.preteyeres.2010.05.003","article-title":"Animal models of choroidal and retinal neovascularization","volume":"29","author":"Grossniklaus","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.exer.2018.05.027_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/archopht.123.4.509","article-title":"Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey","volume":"123","author":"Husain","year":"2005","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.exer.2018.05.027_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neuropharm.2015.08.005","article-title":"Purinergic neurone-glia signalling in cognitive-related pathologies","volume":"104","author":"Illes","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.exer.2018.05.027_bib14","first-page":"107","article-title":"Aminoadipic acid toxic effects on retinal glial cells","volume":"27","author":"Ishikawa","year":"1983","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.05.027_bib15","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"Koh","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.exer.2018.05.027_bib16","first-page":"1542","article-title":"Muller cell outgrowth after retinal detachment: association with cone photoreceptors","volume":"41","author":"Lewis","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.05.027_bib17","first-page":"899","article-title":"Pathogenesis of laser-induced choroidal subretinal neovascularization","volume":"31","author":"Miller","year":"1990","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.05.027_bib18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2337\/diabetes.47.3.445","article-title":"Muller cell changes in human diabetic retinopathy","volume":"47","author":"Mizutani","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.exer.2018.05.027_bib19","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/archophthalmol.2011.210","article-title":"Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates","volume":"129","author":"Nork","year":"2011","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.exer.2018.05.027_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00006982-198202040-00020","article-title":"The toxic effects of glutamate and related compounds in the retina and the brain","volume":"2","author":"Olney","year":"1982","journal-title":"Retina"},{"key":"10.1016\/j.exer.2018.05.027_bib21","first-page":"183","article-title":"The outer limiting membrane (OLM) revisited: clinical implications","volume":"4","author":"Omri","year":"2010","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.exer.2018.05.027_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease","volume":"227","author":"Penn","year":"2008","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.exer.2018.05.027_bib23","first-page":"1971","article-title":"Glial reactivity, an early feature of diabetic retinopathy","volume":"41","author":"Rungger-Brandle","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.05.027_bib24","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1172\/JCI42142","article-title":"Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life","volume":"9","author":"Sapieha","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.exer.2018.05.027_bib25","doi-asserted-by":"crossref","first-page":"15715","DOI":"10.1523\/JNEUROSCI.2841-12.2012","article-title":"Conditional Mullercell ablation causes independent neuronal and vascular pathologies in a novel transgenic model","volume":"32","author":"Shen","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.exer.2018.05.027_bib26","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/jnr.22317","article-title":"Retinal vascular changes after glial disruption in rats","volume":"88","author":"Shen","year":"2010","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.exer.2018.05.027_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1167\/iovs.10-6033","article-title":"Submacular DL-alpha-aminoadipic acid eradicates primate photoreceptors but does not affect luteal pigment or the retinal vasculature","volume":"52","author":"Shen","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.05.027_bib28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/archopht.122.3.353","article-title":"Predilection of the macular region to high incidence of choroidal neovascularization after intense laser photocoagulation in the monkey","volume":"122","author":"Shen","year":"2004","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.exer.2018.05.027_bib29","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/7434","article-title":"Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization","volume":"5","author":"Takahashi","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.exer.2018.05.027_bib30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S2213-8587(16)30052-3","article-title":"Diabetic macular oedema","volume":"5","author":"Tan","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Pt 2","key":"10.1016\/j.exer.2018.05.027_bib31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/eye.1990.41","article-title":"Permeability of ocular vessels and transport across the blood-retinal-barrier","volume":"4","author":"Tornquist","year":"1990","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.exer.2018.05.027_bib32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jneuroim.2004.11.013","article-title":"Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis","volume":"160","author":"van der Flier","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.exer.2018.05.027_bib33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cne.903100203","article-title":"Rod-signal interneurons in the rabbit retina: 2. AII amacrine cells","volume":"310","author":"Vaney","year":"1991","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.exer.2018.05.027_bib34","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2018.05.027_bib35","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.exer.2008.01.004","article-title":"Pharmacological disruption of the outer limiting membrane leads to increased retinal integration of transplanted photoreceptor precursors","volume":"86","author":"West","year":"2008","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2018.05.027_bib36","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1076\/ceyr.22.2.140.5528","article-title":"Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit","volume":"22","author":"Wong","year":"2001","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.exer.2018.05.027_bib37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/02713683.2016.1227448","article-title":"Subchoroidal release of VEGF and bFGF produces choroidal neovascularization in rabbit","volume":"42","author":"Wong","year":"2017","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.exer.2018.05.027_bib38","doi-asserted-by":"crossref","first-page":"16012","DOI":"10.1038\/nrdp.2016.12","article-title":"Diabetic retinopathy","volume":"2","author":"Wong","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.exer.2018.05.027_bib39","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMcp1003934","article-title":"Clinical practice. Retinal-vein occlusion","volume":"363","author":"Wong","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2018.05.027_bib40","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.exer.2018.05.027_bib41","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483517308679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483517308679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T02:52:55Z","timestamp":1720320775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483517308679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":41,"alternative-id":["S0014483517308679"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2018.05.027","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2018.05.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}